Award Number: W81XWH-10-1-0699

TITLE: Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy

PRINCIPAL INVESTIGATOR: Dr. Marjorie Zauderer

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research
New York, NY 10065

REPORT DATE: September 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy

Dr. Marjorie Zauderer
email: zauderem@mskcc.org

Sloan-Kettering Institute for Cancer Research
New York, NY 10065

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

The Wilms’ tumor gene, WT1, encodes transcription factors that regulate cell proliferation, differentiation, and apoptosis. WT1 protein is highly expressed in malignant pleural mesothelioma (MPM), and is a rational target for immunotherapy. We have developed a vaccine comprised of four WT1 heteroclitic peptides that are given together with Montanide and GM-CSF as immunologic adjuvants. This WT1 vaccine was previously tested in a small pilot trial, and shown to be safe and immunogenic. We have chosen to test the efficacy of this vaccine in MPM patients who have minimal disease burden after completion of multimodality therapy, but remain at exceedingly high risk for recurrence. The specific aim of this project is to conduct a multicenter, double-blinded, randomized trial comparing treatment with the WT-1 peptide vaccine + Montanide/GM-CSF to treatment with Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy. The primary endpoint is progression free survival.

Subject Terms
Nothing listed
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>5</td>
</tr>
<tr>
<td>Conclusion</td>
<td>5</td>
</tr>
<tr>
<td>References</td>
<td>6</td>
</tr>
</tbody>
</table>
INTRODUCTION:

The Wilms' tumor gene, WT1, encodes transcription factors that regulate cell proliferation, differentiation, and apoptosis. WT1 protein is highly expressed in malignant pleural mesothelioma (MPM), and is a rational target for immunotherapy. We have developed a vaccine comprised of four WT1 heteroclitic peptides that are given together with Montanide and GM-CSF as immunologic adjuvants. This WT1 vaccine was previously tested in a small pilot trial, and shown to be safe and immunogenic. We have chosen to test the efficacy of this vaccine in MPM patients who have minimal disease burden after completion of multimodality therapy, but remain at exceedingly high risk for recurrence. The specific aim of this project is to conduct a multicenter, double-blinded, randomized trial comparing treatment with the WT1 peptide vaccine + Montanide/GM-CSF to treatment with Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy. The primary endpoint is progression free survival.

BODY:

This project has proceeded as indicated in the approved Statement of Work:

- The peptides were purchased, manufactured, and underwent sterility testing.
  - The peptides were ordered from AmbioPharm, Inc. Once produced, they were vialled under GMP conditions by University of Iowa Pharmaceuticals. The investigational agent completed sterility and stability testing to ensure safety for human use. The vials were delivered to the pharmacy at MSKCC.
- The protocol was reviewed by the various committees at MSKCC and the DOD leading to IRB approval.
  - After IRB approval in September, 2010, the study received approval from the FDA on 12/21/2010. During that time, the protocol was reviewed by the HRPO at the Department of Defense and several comments were made requiring changes to the protocol. The requested changes were made, reviewed by HRPO, and an amendment to the protocol was submitted to the IRB. The amendment was approved on 2/9/11. Final review took place by HRPO and an approval memo was issued on 2/11/11.
  - A start-up meeting was held with the research staff on 2/1/11 to inform all of the participants about the rationale, design, and logistics of this study.
- M.D Anderson Cancer Center received IRB approval for the protocol in August, 2012, but they were unable to enroll their first patient until April, 2013 due to delays related to institutional processes, and FDA and DOD approvals.
- Additional sites have not yet been recruited for participation in the study due to budget constraints.

KEY RESEARCH ACCOMPLISHMENTS:

- The planned randomized phase II trial is open at MSKCC and MDACC and is actively accruing patients. 40 patients have been enrolled including 31 from MSKCC and 9 from MDACC. No treatment related adverse events have occurred.
• An interim analysis was conducted on May 10, 2015. At that time, on the Montanide + GM-CSF arm had 21 patients and greater than 10 out of the first 20 experienced progression within 1 year. On the Montanide + GM-CSF + WT-1 vaccine arm, there were 19 patients and it was too early to assess the futility endpoint. Based on this, the Montanide + GM-CSF arm met the criteria for closure due to futility while the other arm was recommended to continue enrollment and be reassessed for futility once 20 patients are evaluable for progression at one year. Follow up will continue for patients on both arms.
• Dr. Marjorie G. Zauderer became the PI of this clinical trial and the PI for this grant.
• MSKCC has transferred the IND for the WTI vaccine with SELLAS Life Sciences Group. This may help facilitate additional sites to open this trial, which would increase accrual.
• An application for a one-year no cost extension was filed and approved.

REPORTABLE OUTCOMES:

This protocol was highlighted in several presentations which have increased exposure and enrollment. This includes:
ASCO 2011, Chicago, IL - poster presented at Trials in Progress Session
World Conference on Lung Cancer, Amsterdam, Jul 2011, slide presentation
http://www.youtube.com/watch?v=VNUXss6B2uY
Meso Foundation Podcast February 23, 2012
Meso Foundation conference at University of Pennsylvania 2014
Meso Foundation conference at MSK 2015
Planning submission to International Mesotheioma Interest Group 2016 Meeting

CONCLUSION:

The clinical trial is open to enrollment at Memorial Sloan-Kettering and MD Anderson which will continue for the next year. The rate of accrual is slower than expected due to the delays in getting MD Anderson open. A no-cost extension of the grant has been approved. We will reassess for futility on the open arm once 20 patients are evaluable for progression at one year.

REFERENCES:


Patients with Complete Remission from Acute Myeloid Leukemia (AML), Blood 2010; 116(2):171-9.


**APPENDICES:**
None

**SUPPORTING DATA:**
None